Pembrolizumab, Pemetrexed, and Carboplatin Improve Lung Cancer Survival

Bryant FurlowJun 3, 2018Adding pembrolizumab to pemetrexed and carboplatin for advanced nonsquamous NSCLC is associated with improved overall survival at 24 months.

Source: CancerNetwork - June 3, 2018 Category: Cancer & Oncology Authors: A Source Type: news